An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5004 and Absolute Bioavailability of AZD5004 in Healthy Male Participants
Latest Information Update: 13 Apr 2025
At a glance
- Drugs AZD 5004 (Primary)
- Indications Liver disorders; Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AstraZeneca
- 20 Mar 2025 Status changed from not yet recruiting to recruiting.
- 07 Mar 2025 New trial record